Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-488-0460
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions
What is Brainstorm Cell Therapeutics' stock symbol?
Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."
How were Brainstorm Cell Therapeutics' earnings last quarter?
Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) released its quarterly earnings data on Tuesday, August, 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.12. View Brainstorm Cell Therapeutics' Earnings History.
When is Brainstorm Cell Therapeutics' next earnings date?
What price target have analysts set for BCLI?
3 brokers have issued 12-month price objectives for Brainstorm Cell Therapeutics' stock. Their predictions range from $9.00 to $11.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $10.00 in the next year. This suggests a possible upside of 153.2% from the stock's current price. View Analyst Price Targets for Brainstorm Cell Therapeutics.
What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Brainstorm Cell Therapeutics.
Has Brainstorm Cell Therapeutics been receiving favorable news coverage?
Headlines about BCLI stock have trended very negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Brainstorm Cell Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Brainstorm Cell Therapeutics.
Are investors shorting Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics saw a drop in short interest in September. As of September 30th, there was short interest totalling 654,000 shares, a drop of 9.0% from the August 30th total of 718,500 shares. Based on an average daily volume of 128,700 shares, the days-to-cover ratio is presently 5.1 days. Approximately 3.3% of the shares of the stock are short sold. View Brainstorm Cell Therapeutics' Current Options Chain.
Who are some of Brainstorm Cell Therapeutics' key competitors?
Some companies that are related to Brainstorm Cell Therapeutics include Avrobio (AVRO), Prevail Therapeutics (PRVL), Adverum Biotechnologies (ADVM), Precision BioSciences (DTIL), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), PDL BioPharma (PDLI), Eiger Biopharmaceuticals (EIGR), ADMA Biologics (ADMA), LogicBio Therapeutics (LOGC) and La Jolla Pharmaceutical (LJPC).
What other stocks do shareholders of Brainstorm Cell Therapeutics own?
Who are Brainstorm Cell Therapeutics' key executives?
Brainstorm Cell Therapeutics' management team includes the folowing people:
- Dr. Irit Arbel, Founder & Chairperson (Age 59)
- Mr. Chaim Lebovits, Pres & CEO (Age 48)
- Mr. Eyal Rubin, CFO & Treasurer (Age 43)
- Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 61)
- Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 42)
How do I buy shares of Brainstorm Cell Therapeutics?
Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Brainstorm Cell Therapeutics' stock price today?
One share of BCLI stock can currently be purchased for approximately $3.95.
How big of a company is Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics has a market capitalization of $89.07 million. The biotechnology company earns $-13,950,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Brainstorm Cell Therapeutics employs 31 workers across the globe.View Additional Information About Brainstorm Cell Therapeutics.
What is Brainstorm Cell Therapeutics' official website?
How can I contact Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics' mailing address is 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected]
MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)
MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
